Проект инициативных клинических рекомендаций по диагностике и лечению волчаночного нефрита

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939. DOI: 10.1056/NEJMra071297

2. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med. 2011. 365(22):2110-2121. doi: 10.1056/NEJMra1100359

3. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. DOI: 10.1111/j.1523-1755.2004.00443.x

4. Rovin BH, Caster DJ, Cattran DC et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int. 2019;95(2):281-295. DOI: 10.1016/j.kint.2018.11.008

5. Rekvig OP, van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301-311. DOI: 10.1007/s00281-014-0428-6

6. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329-341. DOI: 10.1038/nrneph.2015.33

7. Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781-787.

8. Sengupta M, Morel L. Lupus at the molecular level. Protein Cell. 2011;2(12):941-943. DOI: 10.1007/s13238-011-1123-1

9. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-318. DOI: 10.1191/0961203306lu2305xx

10. Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2019;71(9):1400-1412. DOI: 10.1002/art.40930

11. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. DOI: 10.1002/art.1780350606

12. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.

13. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558. DOI: 10.1056/NEJMoa051135

14. Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. DOI: 10.1016/j.kint.2017.11.023

15. Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473

16. Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9(11):687-694. DOI: 10.1038/nrrheum.2013.103

17. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. DOI: 10.2215/CJN.05780616.

18. Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23(4):1298-1306. DOI: 10.1093/ndt/gfm775

19. Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23(1):149-154. DOI: 10.1681/ASN.2011060558

20. Dube GK, Markowitz GS, Radhakrishnan J et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. DOI: 10.5414/cnp57120

21. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. DOI: 10.1681/ASN.2004050350

22. Hernandez-Molina G, Garcia-Trejo LP, Uribe N et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol. 2015;33(4):503-508.

23. Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715-723. DOI: 10.1038/ki.2012.409

24. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf.

25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., Suppl. 2013;3:1-150. DOI: 10.1038/kisup.2012.73

26. Камышова ЕС. Клинические практические рекомендации KDIGO 2012 по диагностике и лечению Хронической болезни почек (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ. 2017;19(1):23-206.

27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. DOI: 10.1016/j.kint.2023.10.018

28. Mosca M, Costenbader KH, Johnson SR et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol. 2019;71(1):91-98. DOI: 10.1002/art.40674

29. Leuchten N, Milke B, Winkler-Rohlfing B et al. Early symptoms of systemic lupus erythematosus (SLE) re-called by 339 SLE patients. Lupus. 2018;27(9):1431-1436. DOI: 10.1177/0961203318776093

30. Козловская Н.Л., Захарова Е.В. Системная красная волчанка в книге Нефрология. Национальное руководство, краткое издание. Издательство «ГЭОТАР-Медиа». 2014. С.269-287. ISBN: 987-5-9704-3014-9

31. Barbhaiya M, Zuily S, Naden R et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82(10):1258-1270. DOI: 10.1136/ard-2023-224609

32. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25-30. DOI: 10.1191/0961203305lu2055oa

33. Corapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015;17(1):110. DOI: 10.1186/s13075-015-0621-6

34. Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313. DOI: 10.1002/art.39026

35. Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med. 2017;4(1):e000213. DOI: 10.1136/lupus-2017-000213

36. Tamirou F, Lauwerys BR, Dall'Era M et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. DOI: 10.1136/lupus-2015-000123.

37. Wang S, Spielman A, Ginsberg M et al. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol. 2022;17(8):1150-1158. DOI: 10.2215/CJN.01280122

38. Konieczny A, Kasenberg I, Mikołajczak A et al. Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience. Int J of Environ Res Public Health. 2022;19(23):15909. DOI: 10.3390/ijerph192315909

39. Sayer J, McCarthy MP, Schmidt JD. Identification and significance of dysmorphic versus isomorphic hematuria. J Urol. 1990;143(3):545-548. DOI: 10.1016/s0022-5347(17)40015-2

40. Rahman P, Gladman DD, Ibanez D et al. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus. 2001;10(6):418-423. DOI: 10.1191/096120301678646164

41. Ding JYC, Ibanez D, Gladman D, Urowitz MB. Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. J Rheumatol. 2015;42(3):437-440. DOI: 10.3899/jrheum.140415

42. Korbet SM, Whittier WL, Lewis EJ. The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra. 2016;6(2):12-21. DOI: 10.1159/000448487

43. Almaani S, Bhatt U, Arriens C. Creatinine Fluctuation in Patients with Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020;5(8):1302-1305. DOI:10.1016/j.ekir.2020.05.011

44. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021

45. Бобкова ИН, Буланов НМ, Захарова ЕВ и соавт. Клинические практические рекомендации KDIGO 2021 по лечению гломерулярных болезней (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ. 2022;24(4):577-874. DOI: 10.28996/2618-9801-2022-4-577-874

46. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1-S69. DOI: 10.1016/j.kint.2023.09.002

47. Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol. 2013;40(5):630-633. DOI: 10.3899/jrheum.121094

48. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-1782. DOI: 10.1136/annrheumdis-2012-201940

49. Захарова ЕВ. Совместные рекомендации Евро­пейской лиги по борьбе с ревматизмом и Европейской почечной ассоциации-Европейской ассоциации диализа и трансплантации по ведению волчаночного нефрита у взрослых и детей (перевод на русский язык). Нефрология и диализ. 2012;14(4):206-222.

50. Козловская НЛ, Моисеев СВ, Новиков ПИ. Лечение волчаночного нефрита: новые рекомендации EULAR/ERA-EDTA. Клиническая фармакология и терапия. 2013;22(1):62-68.

51. Козловская НЛ, Захарова ЕВ, Коротчаева ЮВ. Гломерулонефрит при системной красной волчанке в книге Национальные клинические рекомендации по лечению гломерулонефритов. Издательство «Белый Ветер». 2015.С.177-200.

52. Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924

53. Козловская НЛ, Соловьев СК, Асеева ЕА и соавт. Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I. Современная ревматология. 2020;14(4):7-15.

54. Jeong S, Yang D, Lee W et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(2):334-342. DOI: 10.1016/j.semarthrit.2018.01.011

55. Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272-1280. DOI: 10.1177/0961203310371154

56. Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(9):3552-3559. DOI: 10.1093/ndt/gfs179

57. Stanley JH, Cornella R, Loevinger E et al. Sonography of systemic lupus nephritis. Am J Roentgenology. 1984;142(6):1165-1168. DOI: 10.2214/ajr.142.6.1165.

58. Longmaid HE 3rd, Rider E, Tymkiw J. Lupus nephritis. New sonographic findings. J Ultrasound Med. 1987;6(2):75-79. DOI: 10.7863/jum.1987.6.2.75

59. Thurman JM, Serkova NJ. Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research. 2015;4:153. DOI: 10.12688/f1000research.6587.2

60. Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part II: gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68(2):192-202. DOI: 10.1016/j.crad.2012.06.109.

61. Conti F, Ceccarelli F, Gigante A et al. Ultrasonographic Evaluation of Renal Resistive Index in Patients with Lupus Nephritis: Correlation with Histologic Findings. Ultrasound in Med Biol. 2014;40(11):2573-2580. DOI: 10.1016/j.ultrasmedbio.2014.06.016

62. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS) – APS nephropathy. Clin Rev Allergy Immunol. 2009;36(2-3):131-140. DOI: 10.1007/s12016-008-8112-z

63. Lalani TA, Kanne JP, Hatfield GA, Chen P. Imaging findings in systemic lupus erythematosus. Radiographics. 2004;24(4):1069-1086. DOI: 10.1148/rg.244985082

64. Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol. 2013;68(2):181-191. DOI: 10.1016/j.crad.2012.06.110

65. van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. DOI: 10.1136/annrheumdis-2013-205139

66. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int. 2007;71(6):491-495. DOI: 10.1038/sj.ki.5002118

67. Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int. 2018;93(1):214-220. DOI: 10.1016/j.kint.2017.07.017

68. Wang H, Ren YL, Chang J et al. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2017;33(1):17-25. DOI: 10.5606/ArchRheumatol.2017.6127

69. Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089

70. van Vollenhoven R, Voskuyl A, Bertsias G et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-561. DOI: 10.1136/annrheumdis-2016-209519

71. Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther. 2012;14:202. DOI: 10.1186/ar3656

72. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28. DOI: 10.1136/ard.2008.101766

73. Pakchotanon R, Gladman DD, Su J, Urowitz MB. More Consistent Antimalarial Intake in First 5 Years of Disease is Associated with Better Prognosis in Patients with Systemic Lupus Erythematous. J Rheumatol. 2018;45(1):90-94. DOI: 10.3899/jrheum.170645

74. Sisó A, Ramos-Casals M, Bové A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008;17(4):281-288. DOI: 10.1177/0961203307086503

75. Pons-Estel GJ, Alarcón GS, McGwin G Jr et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-839. DOI: 10.1002/art.24538

76. Zavala-Miranda MF, Perez-Arias AA, Márquez-Macedo SE et al. Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. Rheumatology. 2023;62(3):1136–1144. DOI: 10.1093/rheumatology/keac407

77. Sciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig. 2017;37(6):519-524. DOI: 10.1007/s40261-017-0518-z

78. Bharati J, Rathi M. Comparison of two steroid regimen. Indian J Nephrol. 2019.;29(5):373-375. DOI: 10.4103/ijn.IJN_299_18

79. Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis. 2022;25(2):121-130. DOI: 10.1111/1756-185X.14265

80. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res. 2018;70(4):582-591. DOI: 10.1002/acr.23322

81. Singh JA, Hossain A, Kotb A et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137-149. DOI: 10.1186/s12916-016-0673-8

82. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-832. DOI: 10.1016/j.autrev.2017.05.017

83. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028-2035. DOI: 10.1681/ASN.2010050472

84. Hu W, Chen Y, Wang S et al. Clinical–Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. DOI: 10.2215/CJN.06720615

85. Hu WX, Chen YH, Bao H et al. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus. 2015;24(10):1067-1075. DOI: 10.1177/0961203315578766

86. Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44(4):561-569. DOI: 10.1016/j.rdc.2018.06.003

87. Wang Y, Yu F, Song D et al. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7):1235-1244. DOI: 10.1093/rheumatology/ket491

88. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. DOI: 10.1038/nrneph.2017.85

89. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. DOI: 10.1002/art.10461

90. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-64. DOI: 10.1136/ard.2008.102533

91. Rijnink EC, Teng YKO, Wilhelmus S et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. DOI: 10.2215/CJN.10601016

92. Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74-87. DOI: 10.1053/j.ajkd.2012.08.041

93. Tunnicliffe DJ, Palmer SC, Henderson L et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922. DOI: 10.1002/14651858.CD002922.pub4

94. Furie R, Rovin BH, Houssiau F et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128. DOI: 10.1056/NEJMoa2001180

95. Collins CE, Cortes-Hernandez J, Garcia MA et al. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020;7(4):949-965. DOI: 10.1007/s40744-020-00243-2

96. Furie R, Rovin BH, Houssiau F et al. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022;17(11):1620-1630. DOI: 10.2215/CJN.02520322

97. Rovin BH, Furie R, Teng YKO et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. DOI: 10.1016/j.kint.2021.08.027

98. Frangou E, Bruchfeld A, Fernandez-Juarez GM et al. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrol Dial Transplant. 2024;39(5):727-730. DOI: 10.1093/ndt/gfad230

99. Appel GB, Contreras G, Dooley M.A et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1012. DOI: 10.1681/ASN.2008101028

100. Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-715. Doi: 10.1053/j.ajkd.2012.11.042

101. Zavada J, Pešickova SS, Ryšava R et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study. Lupus. 2010;19(11):1281-1289. DOI: 10.1177/0961203310371155

102. Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018;21(1):200-207. DOI: 10.1111/1756-185X.13152

103. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606-615. DOI: 10.1007/s10165-009-0218-5

104. Uchino A, Tsukamoto H, Nakashima H et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.

105. Chen W, Tang X, Liu Q et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-244. DOI: 10.1053/j.ajkd.2010.08.036

106. Lee YH, Lee HS, Choi SJ et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-640. DOI: 10.1177/0961203310389486

107. Deng J, Huo D, Wu Q et al. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med. 2012;227(4):281-288. Doi: 10.1620/tjem.227.281

108. Ikeuchi H, Hiromura K, Takahashi S et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618-625. DOI: 10.3109/14397595.2013.844397

109. Mok CC, To CH, Yu KL et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135-1141. DOI: 10.1177/0961203313502864

110. Liu Z, Zhang H, Liu Z et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. DOI: 10.7326/M14-1030

111. Melander C, Sallée M, Trolliet P. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579-587. Doi: 10.2215/CJN.04030808

112. Ramos-Casals M, Soto M.J, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-776. DOI: 10.1177/0961203309106174

113. Díaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-364. DOI: 10.1016/j.autrev.2011.10.009

114. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;6494):1215-1226. DOI: 10.1002/art.34359

115. Moroni G, Raffiotta F, Trezzi B et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014;53(9):1570-1577. DOI: 10.1093/rheumatology/ket462

116. Zickert A, Sundelin B, Svenungsson E et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e000018. DOI: 10.1136/lupus-2014-000018.

117. Galbraith L, Manns B, Hemmelgarn B et al. The steroids in the maintenance of remission of proliferative lupus nephritis (SIMPL) pilot trial. Can J Kidney Health Dis. 2014;1:30. Doi: 10.1186/s40697-014-0030-9

118. Nossent NC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology. 2000;39(9):969-974. DOI: 10.1093/rheumatology/39.9.969

119. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-2089. DOI: 10.1136/ard.2010.131995

120. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. DOI: 10.1056/NEJMoa1014460

121. Feng L Deng J., Huo DM et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton). 2013;18(2):104-110. DOI: 10.1111/nep.12006

122. Deng J, Xie H, Zhu, et al. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis. Clin Nephrol. 2019;91(3):172-179. Doi: 10.5414/CN109450

123. Tamirou F, D'Cruz D, Sangle S et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526-531. DOI: 10.1136/annrheumdis-2014-206897

124. Argolini LM, Frontini G, Elefante E et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. J. Nephrol. 2021;34(2):389-398. DOI: 10.1007/s40620-020-00753-w

125. Chen W, Liu Q, Chen W et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012;21(9):944-952. DOI: 10.1177/0961203312442259

126. Zhang H, Liu Z, Zhou M et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28(12):3671-3678. DOI: 10.1681/ASN.2017030263

127. Roccatello D, Sciascia S, Baldovino S et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123-1130. DOI: 10.1016/j.autrev.2015.07.017

128. Moroni G, Longhi S, Giglio E et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31(Suppl 78):75-81.

129. Frangou E, Anders H-J, Bajema IM et al. Immunosuppression Withdrawal in Patients with Lupus Nephritis. J Am Soc Nephrol. 2024;35(7):955-958. DOI: 10.1681/ASN.0000000000000365

130. Malvar A, Pirruccio P, Alberton V et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338-1344. DOI: 10.1093/ndt/gfv296

131. Alvarado AS, Malvar A, Lococo B et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus. 2014;23(8):840-847. DOI: 10.1177/0961203313518625

132. Tang K-T, Tseng C-H, Hsieh T-Y et al. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis. 2018;21(6):1163-1172. DOI: 10.1111/1756-185X.13321

133. Austin HA, Illei GG, Braun M., Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 2009;20(4):901-911. Doi: 10.1681/ASN.2008060665

134. Mok C, Ying K, Yim C et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009;18(12):1091-1095. DOI: 10.1177/0961203309106602

135. Szeto C-C, Kwan BC-H, Lai FM-M et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology. 2008;47(11): 1678-1681. Doi: 10.1093/rheumatology/ken335

136. Chen W, Tang X, Liu Q et al. Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. Am J Kidney Dis. 2011;57(2):235-244. Doi: 10.1053/j.ajkd.2010.08.036

137. Radhakrishnan J, Moutzouris D-A, Ginzler E.M et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152-160. DOI: 10.1038/ki.2009.412

138. Yap DY, Yu X, Chen XM et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17(4):352-357. DOI: 10.1111/j.1440-1797.2012.01574.x

139. Chavarot N, Verhelst D, Pardon A et al. Rituximab alone as induction therapy for membranous lupus nephritis: a multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. Doi: 10.1097/MD.0000000000007429

140. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: Assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15-20. DOI: 10.1093/ndt/gfn565

141. Mosca M, Bencivelli W, Neri R et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61(4):1502-1509. DOI: 10.1046/j.1523-1755.2002.00280.x

142. Ioannidis JPA, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57(1):258-264. DOI: 10.1046/j.1523-1755.2000.00832.x

143. Rivera F, Mérida E, Illescas ML et al. Mycophenolate in Refractory and Relapsing Lupus Nephritis. Am J Nephrol. 2014;40(2):105-112. DOI: 10.1159/000365256

144. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9-21. DOI: 10.1002/art.25061

145. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-678. DOI: 10.1191/0961203304lu2012oa

146. De Rosa M, Azzato F, Toblli JE et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018;94(4):788-794. DOI: 10.1016/j.kint.2018.05.021

147. Arriens C, Chen S, Karp DR et al. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017;185:3-9. DOI: 10.1016/j.clim.2016.11.019

148. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res. 2000;13(6):406-408. DOI: 10.1002/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2

149. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheum. 2013;27(3):329-340. DOI: 10.1016/j.berh.2013.07.001

150. Fei Y, Wu Q, Zhang W et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. 2013;31(1):62-68.

151. Ogawa H, Kameda H, Amano K, Takeuchi T. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162-169. DOI: 10.1177/0961203309350320

152. Jesus D, Rodrigues M, da Silva JAP, Inês L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27(8):1358-1362. DOI: 10.1177/0961203318758508

153. Tanaka Y, Takeuchi T, Miyasaka N et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatol. 2016;26(1):80-86. DOI: 10.3109/14397595.2015.1060665

154. Weidenbusch M, Römmele C, Schröttle A, Anders H-J. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28(1):106-111. Doi: 10.1093/ndt/gfs285

155. Alshaiki F, Obaid E, Almuallim A et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018.;5(2):118-126. DOI: 10.5152/eurjrheum.2018.17096

156. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. DOI: 10.1016/j.kint.2020.11.003

157. Duran-Barragan S, McGwin G Jr, Vila LM et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus – results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093-1096. DOI: 10.1093/rheumatology/ken208

158. Kanda H, Kubo K, Tateishi S et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14(4):288-292. DOI: 10.1191/0961203305lu2076oa

159. Tse KC, Li FK, Tang S et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus. 2005;14(12):947-952. DOI: 10.1191/0961203305lu2249oa

160. Morales E, Galindo M. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022;81(9):1337-1338. Doi: 10.1136/annrheumdis-2022-222512

161. Onuora S. SGLT2 inhibitors protect podocytes in lupus nephritis. Nat Rev Rheumatol. 2023;19(10):605. DOI: 10.1038/s41584-023-01024-1

162. Zhao XY, Li SS, He YX et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023;82(10):1328-1340. DOI: 10.1136/ard-2023-224242

163. Furer V, Rondaan C, Heijstek M.W et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020.;79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882

164. Chang YS, Liu CJ, Wu TH et al. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: A nationwide population-based study in Taiwan. Rheumatology (Oxford). 2013;52(1):166-172. DOI: 10.1093/rheumatology/kes325

165. Devlin A, Waikar SS, Solomon DH et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken). 2011;63(12):1642-1653. DOI: 10.1002/acr.20607

166. Weng CH, Hsu CW, Yu CC et al. Peritoneal dialysis and haemodialysis in systemic lupus erythematosus patients: Comparison of clinical outcomes. Kidney Blood Press Res. 2009;32(6):451-456. DOI: 10.1159/000266480

167. Contreras G, Pagan J, Chokshi R et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol. 2014;9(11):1949-1956. DOI: 10.2215/CJN.02500314

168. Levy B, Couchoud C, Rougier J-P et al. Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002–2012. Lupus. 2015;24(10):1111-1121. DOI:10.1177/0961203315578763

169. Bataille S, Burtey S, Decourt A et al. Antiphospholipid antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis. Nephrol Ther. 2015;11(1):27-33. DOI: 10.1016/j.nephro.2014.08.005

170. Park ES, Ahn SS, Jung SM et al. Renal outcome after kidney-transplantation in Korean patients with lupus nephritis. Lupus. 2018;27(3):461-467. DOI:10.1177/0961203317725591

171. Jorge A, Wallace ZS, Lu N et al. Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med. 2019;170(4):240-247. DOI: 10.7326/M18-1570

172. Chung MC, Yu TM, Shu KH et al. Influence of pretransplantation dialysis time and lupus activity on outcome of kidney transplantation in systemic lupus erythematosus. Transplant Proc. 2014;46(2):336-338. DOI: 10.1016/j.transproceed.2013.11.085

173. Contreras G, Mattiazzi A, Guerra G et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol. 2010;219(7):1200-1207. DOI: 10.1681/ASN.2009101093

174. Morales JM, Serrano M, Martinez-Flores JA et al. Antiphospholipid Syndrome and Renal Allograft Thrombosis. Transplantation. 2019;103(3):481-486. DOI: 10.1097/TP.0000000000002510

175. Wagenknecht DR, Fastenau DR, Torry RJ et al. Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies. Transpl Int. 2000;(suppl 1):S78–S81. DOI: 10.1007/s001470050280

176. Song D, Wu LH, Wang FM et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):12. DOI: 10.1186/ar4142

177. Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. DOI: 10.1136/annrheumdis-2019-215213

178. Arnaud L, Mathian A, Ruffatti A et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;1393):281-291. DOI: 10.1016/j.autrev.2013.10.014

179. Arnaud L, Mathian A, Devilliers H et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. DOI: 10.1016/j.autrev.2014.10.019

180. Tarr T, Lakos G, Bhattoa HP et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007;16(1):39-45. DOI: 10.1177/0961203306074767

181. Tektonidou MG, Laskari K, Panagiotakos DB et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29-36. Doi: 10.1002/art.24232

182. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. doi: 10.1111/j.1538-7836.2009.03674.x

183. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018. 132(13):13651371. doi: 10.1182/blood-2018-04-848333

184. Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2016. 15(1):38-49. DOI: 10.1016/j.autrev.2015.08.010

185. Legault K, Schunemann H, Hillis C et al. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018;16(8):1656-1664. Doi: 10.1111/jth.14192

186. Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2020;26(7):832-838. DOI: 10.18553/jmcp.2020.26.7.832

187. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-2094. DOI: 10.1182/bloodadvances.2018019596

188. Sciascia S, Radin M, Yazdany J et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. Doi: 10.1007/s00296-017-3686-5

189. Kello N, Khoury LE, Marder G et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. Doi: 10.1016/j.semarthrit.2018.11.005

190. Imbasciati E, Tincani A, Gregorini G et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-525. DOI: 10.1093/ndt/gfn348

191. Buyon JP, Kim MY, Guerra MM et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-163. DOI: 10.7326/M14-2235

192. Tani C, Zucchi D, Haase I et al. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? a multicentre study. Rheumatology (Oxford). 2021;60(12):5610-5619. DOI: 10.1093/rheumatology/keab155

193. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. DOI: 10.1136/annrheumdis-2016-209770

194. Fakhouri F, Schwotzer N, Cabiddu G et al. Glomerular diseases in pregnancy: Pragmatic recommendations for clinical management. Kidney Int. 2023;103(2):264-281. DOI: 10.1016/j.kint.2022.10.029

195. Hoeltzenbein M, Tissen-Diabate T, Fietz AK et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – treatment or hypertension related? an observational cohort study. Pregnancy Hypertens. 2018;13:65-71. DOI: 10.1016/j.preghy.2018.04.022

196. Weber-Schoendorfer C, Kayser A, Tissen-Diabate T et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141. DOI: 10.1097/HJH.0000000000002233

197. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;32493):150-154. DOI: 10.1056/NEJM199101173240303

198. Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;1096):401-404. DOI: 10.1191/096120301678646137

199. Clowse ME, Magder L, Witter F et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640-3647. DOI: 10.1002/art.22159

200. Koh JH, Ko HS, Kwok SK et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24(2):210-217. DOI: 10.1177/0961203314555352

201. Leroux M, Desveaux C, Parcevaux M et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus. 2015;24(13):1384-1391. DOI:10.1177/0961203315591027

202. Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(5):835-848. DOI: 10.1111/bcp.12872.

203. Bramham K, Hunt BJ, Bewley S et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol. 2011;38(9):1906-1913. DOI: 10.3899/jrheum.100997

204. Roberge S, Villa P, Nicolaides K et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141146. DOI: 10.1159/000336662

205. Xu TT, Zhou F, Deng CY et al. Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. J Clin Hypertens (Greenwich). 2015;17(7):567-573. DOI: 10.1111/jch.12541

206. Davidson KW, Barry MJ, Mangione CM et al. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. Journ Am Med Assoc. 2021;326(12):1186-1191. DOI: 10.1001/jama.2021.14781

207. Eudy AM, Siega-Riz AM, Engel SM et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann Rheum Dis. 2018;77(6):855-860. DOI: 10.1136/annrheumdis-2017-212535

208. Lightstone L, Hladunewich MA. Lupus nephritis and pregnancy: concerns and management. Semin Nephrol. 2017;3794):347-353. DOI: 10.1016/j.semnephrol.2017.05.006

209. Gleeson S, Lightstone L. Glomerular disease and pregnancy. Adv Chronic Kidney Dis. 2020;2796):469-476. DOI: 10.1053/j.ackd.2020.08.001

210. Webster P, Wardle A, Bramham K et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014;23(11):1192-1196. DOI: 10.1177/0961203314540353

211. Russell MD, Dey M, Flint J et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62(4):48-88. DOI: 10.1093/rheumatology/keac551

212. Fischer-Betz R, Specker C, Brinks R et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52(6):1070-1076. DOI: 10.1093/rheumatology/kes425

213. de Jesús GR, Rodrigues G, de Jesús NR et al. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16(2):403. DOI: 10.1007/s11926-013-0403-6

214. Mak A, Cheung MW, Cheak AA et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford). 2010;49(2):281-288. DOI: 10.1093/rheumatology/kep373

215. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256-1262. DOI: 10.1097/AOG.0b013e3181deba40

216. Larosa M, Le Guern V, Guettrot-Imbert G et al. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in lupus women: the French GR2 study. Rheumatology (Oxford). 2022;61(9):3657-3666. DOI: 10.1093/rheumatology/keab943

217. Moroni G, Radice A, Giammarresi G et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68(2):234-237. DOI: 10.1136/ard.2008.094508

218. Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-1274. DOI: 10.1136/ard.2009.117200

219. Системная красная волчанка. Рациональная фармакотерапия ревматических заболеваний. Под ред. В.А. Насоновой, Е.Л. Насонова. Издательство «Литтерра». 2003.С.169-180.

220. Соловьев СК, Асеева ЕА, Попкова ТВ и соавт. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14.